Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-06-26

AUTHORS

Toru Adachi, Akira Sato, Masako Baba, Daigo Hiraya, Tomoaki Hasegawa, Kenji Kuroki, Tomoya Hoshi, Kazutaka Aonuma

ABSTRACT

The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF). Landiolol is reported to have good effects in the treatment of SVTs after cardiac surgery. We evaluated 52 patients with SVT and symptoms of HF (NYHA class III/IV, 10/42; EF 32 ± 12 %) on admission because of ischaemic disease (n = 10), non-ischaemic cardiomyopathy (n = 32), or valvular disease (n = 10). Paroxysmal/persistent atrial fibrillation and atrial tachycardia were present in 16 (30 %), 23 (45 %), and 13 (25 %) patients, respectively. The patients first underwent conventional therapy with carperitide, dobutamine, or milrinone. Intravenous landiolol was administered at an infusion rate of 1 μg/kg/min and, if no adverse effects developed, the maintenance dose, titrated to HR and blood pressure response, was increased. At an average dose of 10.8 ± 9.4 μg/kg/min, mean HR significantly decreased significantly from 133 ± 27 to 82 ± 15 beats/min (P < 0.01), whereas systolic blood pressure did not differ from baseline to attainment of an effective dose level (105 ± 21 vs. 101 ± 19 mmHg, P = ns). Within 60 min after initiation of therapy, all patients had achieved a 20 % reduction in HR at the maintenance dose. Transient asymptomatic hypotension requiring cessation of landiolol therapy occurred in three patients. Intravenous administration of landiolol was both effective in rapidly controlling HR for up to 24 h and useful as bridging treatment to additional therapy of oral β blockade, pulmonary vein catheter ablation, or cardiac resynchronisation therapy in patients with HF. More... »

PAGES

464-469

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-013-0377-3

DOI

http://dx.doi.org/10.1007/s00380-013-0377-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020627110

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23801459


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-1 Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Morpholines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tachycardia, Supraventricular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adachi", 
        "givenName": "Toru", 
        "id": "sg:person.01065730035.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065730035.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Akira", 
        "id": "sg:person.0717074353.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717074353.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baba", 
        "givenName": "Masako", 
        "id": "sg:person.01120054420.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120054420.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hiraya", 
        "givenName": "Daigo", 
        "id": "sg:person.0732241722.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732241722.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hasegawa", 
        "givenName": "Tomoaki", 
        "id": "sg:person.0742016406.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742016406.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuroki", 
        "givenName": "Kenji", 
        "id": "sg:person.01310607406.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310607406.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoshi", 
        "givenName": "Tomoya", 
        "id": "sg:person.01127733521.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127733521.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aonuma", 
        "givenName": "Kazutaka", 
        "id": "sg:person.0633316506.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633316506.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf03016588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029531145", 
          "https://doi.org/10.1007/bf03016588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-012-0263-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008600223", 
          "https://doi.org/10.1007/s00380-012-0263-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-013-0335-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026559569", 
          "https://doi.org/10.1007/s00380-013-0335-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-06-26", 
    "datePublishedReg": "2013-06-26", 
    "description": "The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting \u03b2-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF). Landiolol is reported to have good effects in the treatment of SVTs after cardiac surgery. We evaluated 52 patients with SVT and symptoms of HF (NYHA class III/IV, 10/42; EF 32\u00a0\u00b1\u00a012\u00a0%) on admission because of ischaemic disease (n\u00a0=\u00a010), non-ischaemic cardiomyopathy (n\u00a0=\u00a032), or valvular disease (n\u00a0=\u00a010). Paroxysmal/persistent atrial fibrillation and atrial tachycardia were present in 16 (30\u00a0%), 23 (45\u00a0%), and 13 (25\u00a0%) patients, respectively. The patients first underwent conventional therapy with carperitide, dobutamine, or milrinone. Intravenous landiolol was administered at an infusion rate of 1\u00a0\u03bcg/kg/min and, if no adverse effects developed, the maintenance dose, titrated to HR and blood pressure response, was increased. At an average dose of 10.8\u00a0\u00b1\u00a09.4\u00a0\u03bcg/kg/min, mean HR significantly decreased significantly from 133\u00a0\u00b1\u00a027 to 82\u00a0\u00b1\u00a015\u00a0beats/min (P\u00a0<\u00a00.01), whereas systolic blood pressure did not differ from baseline to attainment of an effective dose level (105\u00a0\u00b1\u00a021 vs. 101\u00a0\u00b1\u00a019\u00a0mmHg, P\u00a0=\u00a0ns). Within 60\u00a0min after initiation of therapy, all patients had achieved a 20\u00a0% reduction in HR at the maintenance dose. Transient asymptomatic hypotension requiring cessation of landiolol therapy occurred in three patients. Intravenous administration of landiolol was both effective in rapidly controlling HR for up to 24\u00a0h and useful as bridging treatment to additional therapy of oral \u03b2 blockade, pulmonary vein catheter ablation, or cardiac resynchronisation therapy in patients with HF.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-013-0377-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "keywords": [
      "heart failure", 
      "supraventricular tachyarrhythmias", 
      "maintenance dose", 
      "treatment of SVT", 
      "pulmonary vein catheter ablation", 
      "symptoms of HF", 
      "safe dosing regimen", 
      "transient asymptomatic hypotension", 
      "initiation of therapy", 
      "blood pressure response", 
      "systolic blood pressure", 
      "cardiac resynchronisation therapy", 
      "congestive heart failure", 
      "non-ischemic cardiomyopathy", 
      "persistent atrial fibrillation", 
      "beats/min", 
      "adrenergic blocking agent", 
      "effective dose levels", 
      "intravenous landiolol", 
      "asymptomatic hypotension", 
      "additional therapy", 
      "dosing regimen", 
      "cardiac surgery", 
      "resynchronisation therapy", 
      "valvular disease", 
      "blood pressure", 
      "catheter ablation", 
      "atrial fibrillation", 
      "atrial tachycardia", 
      "conventional therapy", 
      "intravenous administration", 
      "landiolol", 
      "blocking agent", 
      "ischemic diseases", 
      "infusion rate", 
      "patients", 
      "average dose", 
      "dose levels", 
      "therapy", 
      "adverse effects", 
      "pressure response", 
      "dose", 
      "tachyarrhythmias", 
      "disease", 
      "hr", 
      "treatment", 
      "min", 
      "carperitide", 
      "hypotension", 
      "regimen", 
      "tachycardia", 
      "dobutamine", 
      "surgery", 
      "milrinone", 
      "failure", 
      "admission", 
      "cardiomyopathy", 
      "fibrillation", 
      "blockade", 
      "symptoms", 
      "administration", 
      "baseline", 
      "good effect", 
      "cessation", 
      "novel use", 
      "ablation", 
      "effect", 
      "agents", 
      "initiation", 
      "response", 
      "levels", 
      "study", 
      "rate", 
      "reduction", 
      "pressure", 
      "use", 
      "purpose", 
      "landiolol therapy", 
      "vein catheter ablation", 
      "intravenous \u03b21-selective blocker landiolol", 
      "\u03b21-selective blocker landiolol", 
      "blocker landiolol"
    ], 
    "name": "Novel use of the ultra-short-acting intravenous \u03b21-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure", 
    "pagination": "464-469", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020627110"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-013-0377-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23801459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-013-0377-3", 
      "https://app.dimensions.ai/details/publication/pub.1020627110"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_612.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-013-0377-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0377-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0377-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0377-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-013-0377-3'


 

This table displays all metadata directly associated to this object as RDF triples.

277 TRIPLES      22 PREDICATES      129 URIs      118 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-013-0377-3 schema:about N0ca572d2469848048db845de0b6093e2
2 N11a0f8bc65a04c49a1b7f7fe9e4a6496
3 N1d73e32a72fe40bc827c18048fae10ed
4 N2041942691ec4f82b5eb84585027d744
5 N2ca90c8f626946dda55dfa1ec9818579
6 N505581ee55e8431ebe23bd7aa08f67d7
7 N5bd38fb4d2e648a2936d211a9de971d4
8 N8076669aa95d4586a128760434613f16
9 N8c0eb3fd01334900ab1aa70407f6f955
10 N8f99de5eef464954b89afa3fc8c6fec5
11 Nb9aca1417811480385d068d2e521cc96
12 Nbf6575881cdf471abd4e2c0d9708a3a6
13 Nc823f740cbd1417cbc24a239ff3d8bae
14 Ncd9540567c98440ba14e20b04711fc42
15 Nd847748c92cb40a9916bb532c38965db
16 Ne3c594732f8647bfb61dcec443940c3f
17 Nfb0f50a11b6743eb8e6a995e8742a072
18 Nffc3862fb9084ace9794f85a72f63f56
19 anzsrc-for:11
20 anzsrc-for:1102
21 schema:author N89a4d5ee4b844b8684f1e81eaf8d110f
22 schema:citation sg:pub.10.1007/bf03016588
23 sg:pub.10.1007/s00380-012-0263-4
24 sg:pub.10.1007/s00380-013-0335-0
25 schema:datePublished 2013-06-26
26 schema:datePublishedReg 2013-06-26
27 schema:description The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting β-adrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF). Landiolol is reported to have good effects in the treatment of SVTs after cardiac surgery. We evaluated 52 patients with SVT and symptoms of HF (NYHA class III/IV, 10/42; EF 32 ± 12 %) on admission because of ischaemic disease (n = 10), non-ischaemic cardiomyopathy (n = 32), or valvular disease (n = 10). Paroxysmal/persistent atrial fibrillation and atrial tachycardia were present in 16 (30 %), 23 (45 %), and 13 (25 %) patients, respectively. The patients first underwent conventional therapy with carperitide, dobutamine, or milrinone. Intravenous landiolol was administered at an infusion rate of 1 μg/kg/min and, if no adverse effects developed, the maintenance dose, titrated to HR and blood pressure response, was increased. At an average dose of 10.8 ± 9.4 μg/kg/min, mean HR significantly decreased significantly from 133 ± 27 to 82 ± 15 beats/min (P < 0.01), whereas systolic blood pressure did not differ from baseline to attainment of an effective dose level (105 ± 21 vs. 101 ± 19 mmHg, P = ns). Within 60 min after initiation of therapy, all patients had achieved a 20 % reduction in HR at the maintenance dose. Transient asymptomatic hypotension requiring cessation of landiolol therapy occurred in three patients. Intravenous administration of landiolol was both effective in rapidly controlling HR for up to 24 h and useful as bridging treatment to additional therapy of oral β blockade, pulmonary vein catheter ablation, or cardiac resynchronisation therapy in patients with HF.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N90b3d4e0af514b9886abc30006c4cb47
32 Nb6b7a55f27e246e58e7da024309777c3
33 sg:journal.1095887
34 schema:keywords ablation
35 additional therapy
36 administration
37 admission
38 adrenergic blocking agent
39 adverse effects
40 agents
41 asymptomatic hypotension
42 atrial fibrillation
43 atrial tachycardia
44 average dose
45 baseline
46 beats/min
47 blockade
48 blocker landiolol
49 blocking agent
50 blood pressure
51 blood pressure response
52 cardiac resynchronisation therapy
53 cardiac surgery
54 cardiomyopathy
55 carperitide
56 catheter ablation
57 cessation
58 congestive heart failure
59 conventional therapy
60 disease
61 dobutamine
62 dose
63 dose levels
64 dosing regimen
65 effect
66 effective dose levels
67 failure
68 fibrillation
69 good effect
70 heart failure
71 hr
72 hypotension
73 infusion rate
74 initiation
75 initiation of therapy
76 intravenous administration
77 intravenous landiolol
78 intravenous β1-selective blocker landiolol
79 ischemic diseases
80 landiolol
81 landiolol therapy
82 levels
83 maintenance dose
84 milrinone
85 min
86 non-ischemic cardiomyopathy
87 novel use
88 patients
89 persistent atrial fibrillation
90 pressure
91 pressure response
92 pulmonary vein catheter ablation
93 purpose
94 rate
95 reduction
96 regimen
97 response
98 resynchronisation therapy
99 safe dosing regimen
100 study
101 supraventricular tachyarrhythmias
102 surgery
103 symptoms
104 symptoms of HF
105 systolic blood pressure
106 tachyarrhythmias
107 tachycardia
108 therapy
109 transient asymptomatic hypotension
110 treatment
111 treatment of SVT
112 use
113 valvular disease
114 vein catheter ablation
115 β1-selective blocker landiolol
116 schema:name Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure
117 schema:pagination 464-469
118 schema:productId N141145dc808f44d7bde90ed06ddb5ddd
119 N94eaf360a1614706bf03430e67f5e199
120 Nb3e520935ca942e19c0e1cb6cb640654
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020627110
122 https://doi.org/10.1007/s00380-013-0377-3
123 schema:sdDatePublished 2022-01-01T18:31
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher N0773f7d654b4445fa90b9759b6a3ed71
126 schema:url https://doi.org/10.1007/s00380-013-0377-3
127 sgo:license sg:explorer/license/
128 sgo:sdDataset articles
129 rdf:type schema:ScholarlyArticle
130 N02d60a85162c469ba06ee29c73a0033e rdf:first sg:person.01127733521.36
131 rdf:rest N791e121e5e114008b32ee8b570d40d3a
132 N0773f7d654b4445fa90b9759b6a3ed71 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N0ca572d2469848048db845de0b6093e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Female
136 rdf:type schema:DefinedTerm
137 N11a0f8bc65a04c49a1b7f7fe9e4a6496 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Heart Rate
139 rdf:type schema:DefinedTerm
140 N141145dc808f44d7bde90ed06ddb5ddd schema:name dimensions_id
141 schema:value pub.1020627110
142 rdf:type schema:PropertyValue
143 N17159e16e2c740f48d51a2d5894c7ee8 rdf:first sg:person.01310607406.27
144 rdf:rest N02d60a85162c469ba06ee29c73a0033e
145 N1d73e32a72fe40bc827c18048fae10ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Heart Failure
147 rdf:type schema:DefinedTerm
148 N2041942691ec4f82b5eb84585027d744 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 N206d09f2b8854726bade3a6d5430ab7b rdf:first sg:person.01120054420.77
152 rdf:rest N916b2a718bad42b699d5e37bcb3f43b4
153 N2ca90c8f626946dda55dfa1ec9818579 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Blood Pressure
155 rdf:type schema:DefinedTerm
156 N505581ee55e8431ebe23bd7aa08f67d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Time Factors
158 rdf:type schema:DefinedTerm
159 N5bd38fb4d2e648a2936d211a9de971d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Drug Administration Schedule
161 rdf:type schema:DefinedTerm
162 N5ef88f4103854fbf9841790f0b0eb932 rdf:first sg:person.0717074353.90
163 rdf:rest N206d09f2b8854726bade3a6d5430ab7b
164 N791e121e5e114008b32ee8b570d40d3a rdf:first sg:person.0633316506.46
165 rdf:rest rdf:nil
166 N8076669aa95d4586a128760434613f16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Japan
168 rdf:type schema:DefinedTerm
169 N89a4d5ee4b844b8684f1e81eaf8d110f rdf:first sg:person.01065730035.53
170 rdf:rest N5ef88f4103854fbf9841790f0b0eb932
171 N8c0eb3fd01334900ab1aa70407f6f955 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Tachycardia, Supraventricular
173 rdf:type schema:DefinedTerm
174 N8f99de5eef464954b89afa3fc8c6fec5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged
176 rdf:type schema:DefinedTerm
177 N90b3d4e0af514b9886abc30006c4cb47 schema:issueNumber 4
178 rdf:type schema:PublicationIssue
179 N916b2a718bad42b699d5e37bcb3f43b4 rdf:first sg:person.0732241722.10
180 rdf:rest Na152fe56b99b42ad9fe9ae28ad6f7750
181 N94eaf360a1614706bf03430e67f5e199 schema:name pubmed_id
182 schema:value 23801459
183 rdf:type schema:PropertyValue
184 Na152fe56b99b42ad9fe9ae28ad6f7750 rdf:first sg:person.0742016406.32
185 rdf:rest N17159e16e2c740f48d51a2d5894c7ee8
186 Nb3e520935ca942e19c0e1cb6cb640654 schema:name doi
187 schema:value 10.1007/s00380-013-0377-3
188 rdf:type schema:PropertyValue
189 Nb6b7a55f27e246e58e7da024309777c3 schema:volumeNumber 29
190 rdf:type schema:PublicationVolume
191 Nb9aca1417811480385d068d2e521cc96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Morpholines
193 rdf:type schema:DefinedTerm
194 Nbf6575881cdf471abd4e2c0d9708a3a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Adrenergic beta-1 Receptor Antagonists
196 rdf:type schema:DefinedTerm
197 Nc823f740cbd1417cbc24a239ff3d8bae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Urea
199 rdf:type schema:DefinedTerm
200 Ncd9540567c98440ba14e20b04711fc42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Atrial Fibrillation
202 rdf:type schema:DefinedTerm
203 Nd847748c92cb40a9916bb532c38965db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Humans
205 rdf:type schema:DefinedTerm
206 Ne3c594732f8647bfb61dcec443940c3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Male
208 rdf:type schema:DefinedTerm
209 Nfb0f50a11b6743eb8e6a995e8742a072 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Treatment Outcome
211 rdf:type schema:DefinedTerm
212 Nffc3862fb9084ace9794f85a72f63f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Infusions, Intravenous
214 rdf:type schema:DefinedTerm
215 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
216 schema:name Medical and Health Sciences
217 rdf:type schema:DefinedTerm
218 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
219 schema:name Cardiorespiratory Medicine and Haematology
220 rdf:type schema:DefinedTerm
221 sg:journal.1095887 schema:issn 0910-8327
222 1615-2573
223 schema:name Heart and Vessels
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01065730035.53 schema:affiliation grid-institutes:grid.20515.33
227 schema:familyName Adachi
228 schema:givenName Toru
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065730035.53
230 rdf:type schema:Person
231 sg:person.01120054420.77 schema:affiliation grid-institutes:grid.20515.33
232 schema:familyName Baba
233 schema:givenName Masako
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120054420.77
235 rdf:type schema:Person
236 sg:person.01127733521.36 schema:affiliation grid-institutes:grid.20515.33
237 schema:familyName Hoshi
238 schema:givenName Tomoya
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127733521.36
240 rdf:type schema:Person
241 sg:person.01310607406.27 schema:affiliation grid-institutes:grid.20515.33
242 schema:familyName Kuroki
243 schema:givenName Kenji
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310607406.27
245 rdf:type schema:Person
246 sg:person.0633316506.46 schema:affiliation grid-institutes:grid.20515.33
247 schema:familyName Aonuma
248 schema:givenName Kazutaka
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633316506.46
250 rdf:type schema:Person
251 sg:person.0717074353.90 schema:affiliation grid-institutes:grid.20515.33
252 schema:familyName Sato
253 schema:givenName Akira
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717074353.90
255 rdf:type schema:Person
256 sg:person.0732241722.10 schema:affiliation grid-institutes:grid.20515.33
257 schema:familyName Hiraya
258 schema:givenName Daigo
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732241722.10
260 rdf:type schema:Person
261 sg:person.0742016406.32 schema:affiliation grid-institutes:grid.20515.33
262 schema:familyName Hasegawa
263 schema:givenName Tomoaki
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742016406.32
265 rdf:type schema:Person
266 sg:pub.10.1007/bf03016588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029531145
267 https://doi.org/10.1007/bf03016588
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/s00380-012-0263-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008600223
270 https://doi.org/10.1007/s00380-012-0263-4
271 rdf:type schema:CreativeWork
272 sg:pub.10.1007/s00380-013-0335-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026559569
273 https://doi.org/10.1007/s00380-013-0335-0
274 rdf:type schema:CreativeWork
275 grid-institutes:grid.20515.33 schema:alternateName Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan
276 schema:name Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, 305-8575, Tsukuba, Ibaraki, Japan
277 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...